• Alias: GSK2118436
    • Selectively binds to and inhibits the activity of BRAF, which may inhibit the proliferation of tumor cells that contain a mutated BRAF gene
    • FDA approved for the treatment of (1) unresectable or metastatic malignant melanoma in patients with the BRAF V600E mutation, and (2) in combination with trametinib, for BRAF-V600E-mutated metastatic NSCLC
    • Recommended dose: 150 mg orally twice daily on fasting stomach at least 1 hour before or 2 hours after meals
    • Half-life: Parent drug 8 hours; hydroxy-dabrafenib (active metabolite) 10 hours; desmethyl-dabrafenib (active metabolite) 21 to 22 hours
    Other topics in Targeted and Immunotherapy Agents